Armata Pharmaceuticals, Inc.

ARMP | NYSE | CIK: 0000921114 | SIC: 2836 Biological Products, (No Diagnostic Substances) | active
Los Angeles, California
Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Its pipeline includes AP-PA02, an inhaled phage targeting Pseudomonas aeruginosa in cystic fibrosis, and AP-SA02, targeting Staphylococcus aureus. The company has completed three Phase 2 randomized, double-blind, placebo-controlled clinical trials and operates a cGMP-compliant bacteriophage manufacturing facility in Los Angeles.
antibiotic-resistant-bacterial-infectionscystic-fibrosischronic-pulmonary-diseaseacute-systemic-bacterial-infectionscurrent-good-manufacturing-practices-(cgmp)
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/ARMP
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
AP-PA02platformInhaled bacteriophage therapeutic targeting Pseudomonas aeruginosa, primarily for chronic pulmonary infections in cystic fibrosis patients.
AP-SA02platformBacteriophage therapeutic targeting Staphylococcus aureus for acute systemic bacterial infections.

Partnerships

PartnerTypeDescription
Cystic Fibrosis FoundationdevelopmentCollaboration supporting development of phage therapeutics for cystic fibrosis-related bacterial infections.
U.S. Department of DefensestrategicPartnership including a $26.2 million DoD award supporting bacteriophage therapeutic development.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/ARMP/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub